America's health at stake

Scientists searching for cures to cancer, diabetes, Alzheimer’s and other deadly illnesses may soon lose their funding, due to a misguided new proposal from Secretary of Health and Human Services Alex Azar.
 
The proposal would gradually reduce Medicare’s reimbursement rate for advanced drugs administered in hospitals, clinics and doctor’s offices by 30 percent. Mr. Azar claims these price controls “will save $17 billion in Medicare drug spending over the next five years.”
 
It’s true that price controls would save the government money, at least initially. But they’d also deter investors from pouring money into risky, expensive — but potentially game-changing — biopharmaceutical research projects.
 
The cuts to research funding would make it much harder for scientists to discover the cures of tomorrow. Those future medicines wouldn’t just save lives — they’d also save the government money by stemming the rising tide of chronic disease. Mr. Azar’s price-control proposal is penny-wise and pound-foolish.
 
Drug research is ludicrously expensive and fraught with pitfalls. Most research projects fail in the lab. And roughly 9-in-10 experimental drugs that emerge from the lab and enter human trials fail to gain FDA approval. This high failure rate explains why it takes almost $3 billion to develop just one drug.
 
Unlike most European nations, which impose strict price controls on medicines, the United States has a relatively free market for drugs. The ability to earn a sizeable return on successful drugs explains why a majority of world’s new drugs are invented in America. America’s researchers are currently developing more than 3,000 new medicines.
 
 
Sign Up for Our Email Newsletter

RECENT NEWS

Vaper Madness

Vaper Madness

E-cigarettes, while not a cure for nicotine dependence, can help reduce the death and disease caused by combustible tobac...  Read more

Three ways Congress can lower seniors’ pharmacy bills

Three ways Congress can lower seniors’ pharmacy bills

Here are three ways Congress can improve Medicare Part D to lower seniors’ drug tabs....  Read more

FDA Hears Concerns About The Unregulated CBD Market

FDA Hears Concerns About The Unregulated CBD Market

What most speakers agreed on: the need for federal CBD oversight for production quality, more testing and research and be...  Read more

DRUGWONKS BLOG